HISTORY OF OUTCOME MEASURES FOR MYASTHENIA GRAVIS

被引：40
作者：
Burns, Ted M. [1 ]
机构：
[1] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA
来源：
MUSCLE & NERVE | 2010年 / 42卷 / 01期
关键词：
myasthenia gravis; outcome measures; MG Composite; MG-QOL15; rating scales; QUALITY-OF-LIFE; SELF-ADMINISTERED QUESTIONNAIRE; ALTERNATE-DAY PREDNISONE; LONG-TERM CORRELATION; MYCOPHENOLATE-MOFETIL; DOUBLE-BLIND; INTRAVENOUS IMMUNOGLOBULIN; ACETYLCHOLINE-RECEPTORS; RANDOMIZED-TRIAL; CLINICAL-TRIAL;
D O I：
10.1002/mus.21713
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
This review illustrates how measurements of clinical status in patients with myasthenia gravis have evolved from clinical descriptions and estimates of mortality rates to more sophisticated evaluative instruments, including numerical rating scales that measure strength, endurance, quality of life, and activities of daily living. The rationale and use of weighting and the importance of patient-reported outcomes are also discussed. The measurement of the steroid-sparing effect of an immunosuppressant is also reviewed. Muscle Nerve 42: 5-13, 2010
引用
收藏
页码：5 / 13
页数：9
相关论文
共 50 条
  • [41] Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
    Imai, Tomihiro
    Suzuki, Shigeaki
    Nagane, Yuriko
    Uzawa, Akiyuki
    Murai, Hiroyuki
    Utsugisawa, Kimiaki
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [42] Targeted Treatments for Myasthenia Gravis in Children and Adolescents
    Ramdas, Sithara
    Painho, Teresa
    Vanegas, Maria I.
    Famili, Dennis T.
    Lim, Ming J.
    Jungbluth, Heinz
    PEDIATRIC DRUGS, 2024, 26 (06) : 719 - 740
  • [43] Conventional and emerging treatments and controversies in myasthenia gravis
    Evoli, Amelia
    Damato, Valentina
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (05) : 445 - 456
  • [44] Treatment of Myasthenia Gravis Based on Its Immunopathogenesis
    Kim, Jee Young
    Park, Kee Duk
    Richman, David P.
    JOURNAL OF CLINICAL NEUROLOGY, 2011, 7 (04): : 173 - 183
  • [45] Italian recommendations for the diagnosis and treatment of myasthenia gravis
    Evoli, Amelia
    Antonini, Giovanni
    Antozzi, Carlo
    DiMuzio, Antonio
    Habetswallner, Francesco
    Iani, Cesare
    Inghilleri, Maurizio
    Liguori, Rocco
    Mantegazza, Renato
    Massa, Roberto
    Pegoraro, Elena
    Ricciardi, Roberta
    Rodolico, Carmelo
    NEUROLOGICAL SCIENCES, 2019, 40 (06) : 1111 - 1124
  • [46] RITUXIMAB TREATMENT OF MYASTHENIA GRAVIS: A SYSTEMATIC REVIEW
    Tandan, Rup
    Hehir, Michael K., II
    Waheed, Waqar
    Howard, Diantha B.
    MUSCLE & NERVE, 2017, 56 (02) : 185 - 196
  • [47] Treatment and clinical research in myasthenia gravis - How far have we come?
    Barohn, Richard J.
    MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE, 2008, 1132 : 225 - 232
  • [48] Immunosuppressive therapies in myasthenia gravis
    Sanders, Donald B.
    Evoli, Amelia
    AUTOIMMUNITY, 2010, 43 (5-6) : 428 - 435
  • [49] Role of complement in myasthenia gravis
    San, Pyae Phyo
    Jacob, Saiju
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [50] Myasthenia gravis: an update for the clinician
    Sieb, J. P.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 408 - 418
12345